SCHEMBL751121

SCHEMBL751121

Cc1n[c]cc(NC(=O)CN(C)C)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.39
MAPT P10636 2/20 0.37
ABL1 P00519 1/20 0.37
GLA P06280 1/20 0.35
ALDH1A1 P00352 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
RAB9A P51151 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
TLR9 Q9NR96 1/20 0.33
TLR8 Q9NR97 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32
TUBB4B P68371 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL765425 0.77 L3MBTL1 (0.41) L3MBTL1ADORA2AADORA1
SCHEMBL750983 0.72 HPGD (0.49) ABL1L3MBTL1RAB9AADORA2AADORA1
SCHEMBL752358 0.70 L3MBTL1 (0.50) MAPTALDH1A1L3MBTL1RAB9AADORA1
SCHEMBL27567000 0.68 TUBB4A (0.40) PARP1MAPTABL1ALDH1A1L3MBTL1
SCHEMBL2629367 0.67 NOTUM (0.52) PARP1MAPTABL1GLARAB9A
SCHEMBL21892294 0.67 RAB9A (0.59) PARP1MAPTALDH1A1RAB9A
SCHEMBL15743907 0.66 RAB9A (0.67) MAPTL3MBTL1RAB9A
SCHEMBL4813580 0.66 MAPT (0.48) PARP1MAPTALDH1A1L3MBTL1TAAR1
SCHEMBL10275025 0.65 RAB9A (0.59) MAPTALDH1A1L3MBTL1RAB9A
SCHEMBL13892050 0.65 PARP1 (0.51) PARP1MAPTABL1GLAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PARP1 1198/4885MAPT 3169/4885ABL1 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.